No abstract

Describir las características clínicas y socio-demográficas de las personas con infección por el VIH atendidas en los servicios hospitalarios y su evolución temporal.  Estimar la prevalencia de conductas de riesgo para el VIH en la población de estudio.  Estimar la prevalencia de los pacientes que siguen tratamiento antirretroviral y definir las características de estos.  Describir las características particulares de los pacientes con origen en otros países. Métodos: Tipo de estudio: Estudio observacional, descriptivo de corte transversal realizado en un día prefijado. Población de estudio: Pacientes con diagnóstico de VIH en contacto con el Sistema Nacional de Salud. Ámbito: Hospitales del Sistema Nacional de Salud en las comunidades autónomas que participan de forma voluntaria en el estudio. Periodo: 2003-2018. Criterios de inclusión: Pacientes con diagnóstico VIH que se encuentren el día de la encuesta en régimen de hospitalización, consulta externa u hospital de día. Criterios de exclusión: Pacientes con diagnóstico VIH ingresados o tratados en otros servicios ajenos a la unidad VIH o enfermedades infecciosas en el día de la encuesta, que no hayan sido objeto de interconsulta. Recogida de datos: Cuestionario cumplimentado por el personal médico responsable de cada paciente. Análisis: Descriptivo y bivariante. Para analizar la evolución anual de proporciones se ha utilizado el test de χ 2 de tendencia. Resultados: Se presentan los resultados correspondientes a la encuesta realizada en 2018 y el análisis del periodo 2003-2018. Conclusiones: Encuesta Hospitalaria de pacientes con infección por el VIH. Resultados 2018.

Discontinuations due to any reason tended to be less common with elvitegravir, but discontinuations due to toxicity did not differ among integrase inhibitors. Neuropsychiatric toxicity leading to drug discontinuation was more frequent with dolutegravir.

No abstract

. At baseline, both groups were well balanced: 73% male; 63% HCV genotype 1 through 4; 29% had fibrosis index of 3 or greater. The overall SVR was 44% (42% PEG 2b versus 46% PEG 2a, P ‫؍‬ 0.65). Among genotypes 1 through 4, SVRs were 28% versus 32% (P ‫؍‬ 0.67) and 62% versus 71% (P ‫؍‬ 0.6) in genotypes 2 through 3 for PEG 2b and PEG 2a, respectively. Early virological response (EVR; >2 log reduction from baseline or negative HCV-RNA at week 12) was 70% in the PEG 2b group and 80% in the PEG 2a group (P ‫؍‬ 0.13), reaching a positive predictive value of SVR of 64% and a negative predictive value of 100% in both arms. Side effects were present in 96% of patients but led to treatment discontinuation in 10% of patients (8% on PEG 2b and 13% on PEG 2a, P ‫؍‬ 0.47). Conclusion: In patients with HIV, HCV therapy with PEG 2b or PEG 2a plus RBV had no significant differences in efficacy and safety. (HEPATOLOGY 2009;49:22-310.)

No abstract

Highlights Almost two thirds of patients with SARS-CoV-2 infection present with hypocalcemia at hospital admission. Hypocalcemia at admission is related to high oxygen support requirement any time during hospitalization. Patients with hypocalcemia at admission had two times more probability to be admitted to the Intensive Care Unit during hospitalization than patients with normal calcium at admission.

Background The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is mainly based on robust, pivotal clinical trials. Objectives To provide data on clinical use of BIC/FTC/TAF in real life. Patients and methods This was an observational, retrospective and single-centre study. We included all adult, treatment-naive (TN) and treatment-experienced (TE) people living with HIV (PLWH) starting BIC/FTC/TAF from 8 June 2018. We evaluated effectiveness [on treatment (OT), modified intention-to-treat (mITT) and intention-to-treat (ITT)], tolerability and safety in those patients who reached 6 months of follow-up (M6). Results We included 1584 PLWH [213 TN (13%) and 1371 TE (87%)]. The median (IQR) follow-up was 16 (7–21) months, with 81% and 53% of PLWH reaching M6 and M12, respectively. By OT, mITT and ITT, HIV-RNA <50 copies/mL was 77%, 70% and 62% at M6 and 92%, 77% and 63% at M12 for TN PLWH and 94%, 89% and 83% at M6 and 93%, 85% and 78% at M12 for TE PLWH, respectively. In PLWH carrying an M184V/I substitution, OT RNA <50 copies/mL was 89.5% at M6. The median CD4 cell count increased from 329 to 511/μL in TN PLWH and from 630 to 683/μL in TE PLWH at M6. Of the total, 1148 (88%) PLWH continued on BIC/FTC/TAF at M6. The most frequent known reason for discontinuation was toxicity [42 (69%) cases]; only 7 cases were considered virological failures (0.6% of the total OT cohort at M6), with no emerging resistance substitutions. Conclusions In real life, BIC/FTC/TAF showed high rates of virological suppression and also in PLWH carrying lamivudine/emtricitabine resistance substitutions. The tolerability and safety of BIC/FTC/TAF were good, with high persistence observed for patients on this regimen at M6.